Drug Discovery 2024: Connecting Minds, Transforming Science, Empowering Community will take place at ExCeL London from 2–3 October.
From ELRIG Ltd.
There will also be a TechTheatre covering sustainability in drug discovery, robotics, automation, and AI, as well as 260 posters and over 200 exhibitors. Early-stage companies will have the opportunity to exhibit as part of the Breakthrough Zone, and early-career professionals can attend the dedicated ‘Network Like a Boss’ event and Learning Hub. ELRIG will also be hosting school students as part of its ‘Big Adventures in Tiny Lab Coats’ initiative.
Marcus Schindler was appointed Executive Vice President for Research and Early Development and CSO at Novo Nordisk in 2021. Prior to joining the company in 2018 as Senior Vice President for External Innovation and Strategy and later Senior Vice President for Global Drug Discovery, Prof Schindler was Vice President, Head of Cardiovascular and Metabolic Diseases Innovative Medicines at AstraZeneca and Head of Research at Prosidion.
Aging Cell Gene Gene Therapy Laboratory Nanoparticles Nanoscience Research
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
ELRIG UK and SRG announce partnership to advance life science professionals in drug discoveryThe European Laboratory Research & Innovation Group (ELRIG) UK, a not-for-profit, volunteer-led organization for the drug discovery community, today entered into a partnership with SRG, leaders in life science recruitment, to support the advancement of science professionals in their careers.
Read more »
Alzheimer's drug development pipeline: Positive results, new insight on biomarkers position 2024 as 'learning year'The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials.
Read more »
Kaposi sarcoma discovery and mouse model could facilitate drug developmentResearchers at UNC Lineberger Comprehensive Cancer Center, after decades of research efforts, have developed a mouse model of Kaposi sarcoma that could be key to the development of new drugs to treat the disease. Kaposi sarcoma is a cancer that is the most common cancer in people living with HIV.
Read more »
Shape-shifting cancer cell discovery reveals potential skin cancer drug targetsCancer cells can change shape to travel around the body and spread (metastasize), but how they know when to do this has remained elusive.
Read more »
Gene Therapy and Drug Discovery Offer Hope for Polycystic Kidney DiseaseResearchers have discovered that a single normal copy of a defective gene can prevent the formation of dangerous cysts in polycystic kidney disease (PKD). This finding opens up the potential for gene therapy to treat the disease. Additionally, a glycoside drug has been found to bypass the effects of the defective gene. The study, funded by the NIH, could lead to new therapeutic approaches for PKD, a life-threatening inherited kidney disorder.
Read more »
The Role of Erythropoietin in LNP-Mediated mRNA Drug DiscoveryErythropoietin (EPO) is a glycoprotein hormone produced naturally in the kidneys, stimulating red blood cell creation. LNP-mediated mRNA drugs utilize lipid nanoparticle (LNP) technology to deliver modified mRNA into cells. Human EPO plays a role in LNP-mediated mRNA drug discovery by serving as a carrier for mRNA in drug development.
Read more »